Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBSIL Drug Formulary Coverage & PA Update | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedBlue Cross Blue Shield - IllinoisPolicy N/A

    BCBSIL Prescription Drug Formulary (October 2025)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Illinois policy alerts

    Know when Blue Cross Blue Shield - Illinois releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Blue Cross Blue Shield of Illinois outpatient prescription drug formulary that governs covered medications, coverage rules (including prior authorization, step therapy, quantity limits), and member cost-sharing for specified BCBSIL plans.

    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyBCBSIL Prescription Drug Formulary (October 2025)
    Policy CodePolicy N/A
    Change TypeFormulary additions and tier/UM updates (material)
    Effective DateOct 1, 2025
    Last ReviewOct 1, 2025
    Next Review DateOct 1, 2025
    Key ActionSubmit prior authorization requests using BCBSIL provider forms or the phone number on the member ID card when 'PA' appears on a drug line.
    SourceLink
    POLICY UPDATE CHANGES

    Multiple products (including Freestyle test strips and control solutions, Medisense control solutions, Optiumez test strips, Precision test strips, COVID-19 vaccines, and numerous specialty drugs) were added to the formulary with specified new tiers.

    Several products had tier changes (e.g., JYNARQUE, MELPHALAN, PRETOMANID, PYRUKYND, RIBAVIRIN) moving to new tiers.

    Utilization management changes: select ondansetron and granisetron strengths had quantity limits removed; nilotinib had a quantity limit added; VARUBI QL removed.

    New Tier and/or Coverage Restriction = Tier 3 or Tier 4 assignments for numerous specialty biologics and oncology/rare disease drugs (examples: GOMEKLI Tier 4; OMVOH Tier 3; SPEVIGO Tier 4; TRYNGOLZA Tier 4; VANRAFIA Tier 4).

    Oct 2025formulary effective/update month
    Blue Advantage HMOplans referenced
    PA & STcoverage controls used
    30/90 daystypical dispensing supply
    24 hrsexpedited exception timeframe
    90 dayshome delivery supply

    Coverage Criteria and Controls

    Formulary coverage controls

    Coverage of outpatient prescription drugs is governed by formulary placement, benefit plan details, and utilization controls. Drugs may be covered when plan and utilization requirements are met.

    Formulary coverage: Drug is listed on the BCBSIL drug list and is eligible for coverage under the outpatient pharmacy benefit when consistent with the member's specific plan benefits and any applicable utilization controls (PA, ST, QL).

    Formulary organized by therapeutic class; check member plan for tier-specific cost sharing.

    Prior Authorization: Coverage requires prior authorization where 'PA' is indicated on the product line. Providers must submit PA requests using BCBSIL forms or the provider portal.PA approval valid for the lesser of 6 months or length of treatment (maintenance meds: lesser of 12 months or length of treatment)

    If BCBSIL does not respond within 72 hours for non-urgent requests or 24 hours for expedited requests, the request is deemed granted.

    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyBCBSIL Prescription Drug Formulary (October 2025)
    Policy CodePolicy N/A
    Change TypeFormulary additions and tier/UM updates (material)
    Effective DateOct 1, 2025
    Last ReviewOct 1, 2025
    Next Review DateOct 1, 2025
    Key ActionSubmit prior authorization requests using BCBSIL provider forms or the phone number on the member ID card when 'PA' appears on a drug line.
    SourceLink
    On This Page
    Coverage Criteria and ControlsCoding and Drug Identifier TablesProvider Responsibilities and Operational GuidanceKey and DefinitionsInitial Therapy RestrictionsStep Therapy RequirementsQuantity and Dispensing LimitsSite of Care and DistributionBackground and Scope
    Step Therapy: Step therapy (ST) may require trial of specified alternative medications before coverage of certain drugs; where present, 'ST' will appear in the Coverage Requirements and Limits column.

    Exceptions to ST may be requested and are reviewed per exception process.

    Dispensing/Quantity Limits: Dispensing limits (QL/DL) specify maximum quantity per prescription or time period; prescriptions exceeding QL may result in member financial liability for excess quantity.See product-level QL entries for numeric limits

    Some state laws may prohibit coverage beyond dispensing limits for controlled substances.

    Special coverage indicators: Products may be marked CW (Cost Waived), IC (Illinois Code Compliance), OC (Oral Cancer), or AC (ACA Preventive); these indicators affect cost-sharing or coverage when regulatory conditions are met.

    Coverage and cost-sharing depend on the member's benefit plan and regulatory criteria.

    Pharmacy Benefit Coverage and Utilization

    Covered when plan rules and utilization management criteria are met

    Core conditions: 1) Drug is on the BCBSIL drug list or covered via an approved exception; 2) Any applicable prior authorization, quantity/dispensing limits, and tier restrictions are satisfied; 3) For products with regulatory indicators (AC, IC, OC, CW), applicable regulatory or program conditions are met.

    Monthly updates may add PA/QL or tier changes; use exception process when appropriate.

    Quantity-limited coverage examples

    Coverage and limits for listed drugs as shown in excerpt

    Quantity-limited drugs: Certain drugs are covered only up to specified quantity limits (QL). Examples include: acetaminophen-codeine solution QL 2700 mL/30 days; butorphanol nasal solution QL 5 mL/30 days; 100 mcg/hr patch QL 15 patches/30 days; BELBUCA QL 60 films/30 days; multiple morphine ER products QL 60–90 units/30 days; lidocaine oint/patch QL 120 g or 120 patches/30 days.See individual product QL entries

    Prescribers should ensure dispensed quantity aligns with product-level QL to avoid member liability.

    Prior authorization / limited distribution

    Prior authorization and program flags

    PA and special flags: Products annotated with PA require prior authorization before coverage; LD (Limited Distribution) denotes restricted distribution channels; SP (Specialty) indicates specialty handling. Example entries: Lidocaine Oint 5% lists PA and QL; ARIKAYCE lists LD, PA, QL and SP.N/A

    Providers must obtain PA when indicated and may need to use specified specialty channels for LD products.

    Cost-waived opioid reversal agents

    Cost-waived coverage for naloxone products

    CW naloxone products: Multiple naloxone formulations and brands (e.g., nasal sprays, prefilled syringes, auto-injectors) are designated CW (Cost Waived) indicating mandated $0 member cost-sharing for those products under applicable Illinois programs or benefit rules.N/A

    Although cost-waived, pharmacy documentation or program compliance may be required.

    Formulary coverage indicators

    Coverage and restrictions as indicated on product lines

    Formulary entries: Products are listed with tier designations and Coverage Requirements and Limits such as PA (prior authorization), QL (quantity limits), ST (step therapy) and other flags. Specific clinical criteria for coverage are indicated on individual product lines when present.

    Refer to each product row for numeric QL, presence of PA/ST, and any regulatory indicators.

    Formulary control markers

    Coverage and restriction markers present in this excerpt (applies when marker appears next to drug):

    Formulary control markers: When PA is listed, prior authorization is required. When QL is listed, a dispensing/quantity limit applies. LD indicates limited distribution; OC flags oral cancer medications; SP denotes specialty drugs; tier codes (P/NP/p/np) indicate formulary tiering and affect cost-sharing.

    These markers are operational controls shown on product lines and must be followed for coverage.

    Formulary control flags

    Coverage and utilization controls applied to listed outpatient drugs

    Coverage flags: Entries use coverage codes: AC (ACA Preventive), PA (Prior Authorization), QL (Quantity Limits), CW (Cost Waived), IC (Illinois Code Compliance), ST (Step Therapy), SP (Specialty), LD (Limited Distribution). Presence of these flags indicates applicable administrative controls.

    Failure to meet flag requirements may result in denial or member liability.

    Quantity limits

    Quantity limits applied per product

    Quantity limits: Product-level QL statements (for example: QL (30 tablets/30 days); QL (4 tablets/365 days); QL (720 mL/30 days)) define maximum covered dispensing per time period. Prescriptions exceeding QL may require prior authorization or be denied for the excess amount.see product-level QL values

    Confirm numeric QL on the product row before dispensing.

    Per-product coverage and quantity limits

    Coverage and dispensing limits are specified per drug/formulation as listed below.

    SOLIQUA 100/33: Listed with Coverage Requirements and Limits = QL (18 mLs/30 days).QL 18 mLs/30 days

    See product line for tier and dispensing rules.

    TRULICITY (dulaglutide): Coverage Requirements and Limits = PA, QL (4 pens/28 days).QL 4 pens/28 days

    Prior authorization required when PA is indicated.

    Emergency glucagon products (BAQSIMI, GVOKE, ZEGALOGUE): Designated CW (Cost Waived) in certain pack configurations indicating $0 member cost-sharing under applicable rules.variable per product

    Intended for emergency hypoglycemia; some entries also show Tier = P.

    Insulins (multiple brands): Many insulin products list Coverage Requirements and Limits = IC and QL (100 mLs/30 days).QL 100 mLs/30 days

    IC indicates Illinois Code Compliance and may affect cost-sharing and documentation.

    Formulary product coverage rows

    Coverage and restrictions by product (selected examples from this section):

    Anticoagulants: Oral anticoagulants (e.g., PRADAXA, XARELTO, ELIQUIS) are listed with quantity limits and tier designations; some formulations (suspensions, pellet packs) have distinct QL specifications.Product-level QL as listed (e.g., PRADAXA 60/120 packets/30 days; rivaroxaban suspension 600–620 mLs/30 days)

    Confirm exact QL and tier on the product row prior to dispensing.

    Hemostasis and coagulation product coverage

    Coagulation factors and hemophilia-related therapies

    Hemophilia/coagulation factors: Many coagulation factor products (ADVATE, ALPHANATE, ALPROLIX, ELOCTATE, HEMLIBRA, etc.) are designated SP and commonly include LD, PA and QL flags. Typical QL examples include 1 mL/30 days, 1 vial/30 days, or 4 vials/28 days depending on product and presentation.See product-line QL for exact units

    Prior authorization and limited distribution frequently apply to these agents.

    The pharmacy benefit does not cover compounded medications, repackaged medications, or drugs that are not FDA‑approved, unless a specific exception is noted. This exclusion is described in the Coverage Considerations section and applies unless the formulary or plan materials explicitly identify coverage for a particular compounded, repackaged, or non‑FDA product.

    Prescription products that have an available over‑the‑counter (OTC) equivalent may not be covered under the pharmacy benefit. Members and providers should refer to the member's specific benefit materials for plan‑level OTC exclusions and payment obligations.

    Medications that are administered by a health care professional (i.e., provided in a clinic, infusion center, or provider office) are generally not covered under the outpatient pharmacy benefit

    Within the excerpted formulary sections there are no additional explicit exclusions listed beyond the general exclusions already described (e.g., compounded, repackaged, non‑FDA products, OTC equivalents). Refer to plan documents for any plan‑specific exclusions not shown in this excerpt.

    No explicit exclusions are stated in these chunks of the formulary excerpt. The document's key and coverage notes define program flags and typical exclusions, but specific additional exclusions are not present in the cited segments.

    Coding and Drug Identifier Tables

    Monthly drug change entries (by drug name)mixed
    AEROCHAMBERZGOAEROCHAMBERZGO ANTI-STATIC VALVED HOLDING CHAMBER — Addition, Tier 3
    AFLURIA 2025-2026influenza virus vaccine — Addition, Tier 3
    ANALPRAM HChydrocortisone acetate w/ pramoxine perianal lotion — Addition, Tier 4
    ANZEMETdolasetron mesylate 50 mg — UM change, QL Removed
    AUSTEDO XR PATIENT TITRATION KITdeutetrabenazine titration pack — UM change, QL Added
    BESREMIropeginterferon alfa-2b prefilled syringe 500 mcg/mL — Tier Change to Tier 3
    CAPLYTA 10.5/21/42 mglumateperone tosylate capsules — Addition, Tier 4
    CTEXLIchenodiol 250 mg — UM change, PA and QL Added
    dronabinol caps 2.5/5/10 mgUM change, QL Removed
    FERRIC CITRATEferric citrate 1 g — Addition, Tier 4
    1–10 of 17
    1/2
    Not procedural codes — strength/packaging identifiers from formularymixed
    100 mcg/hrpatch (listed with QL 15 patches/30 days)
    120-12 mg/smlcodeine solution concentration
    10 mgl/mlbutorphanol tartrate nasal solution strength
    590 mg/8.4mlARIKAYCE (amikacin sulfate liposome inhalation suspension)
    75 mcg - 900 mcg (various)BELBUCA buprenorphine buccal film strengths
    8 mg/0.1mlKLOXXADO naloxone nasal spray
    4 mg/0.1mlnaloxone nasal spray (multiple brands)
    5 mg/0.5mlZIMHI prefilled syringe strength (example formatting present)
    Selected Specialty/Inhaled antibacterialsmixedCovered
    ARIKAYCEamikacin sulfate liposome inhal suspension 590 mg/8.4 ml - Coverage Limits: LD, PA, QL (235.2 mls/28 days), SP
    TOBI PODHALERtobramycin inhalation capsules 28 mg - Coverage Limits: PA, QL (224 capsules/56 days), SP
    TOBRAMYCIN (nebu soln 300 mg/ml)Coverage Limits: LD, PA, QL (56 containers/56 days), SP
    CAYSTONaztreonam lysine for inhalation 75 mg - Coverage Limits: LD, QL (1 kit/56 days), SP
    Selected oral antibiotic quantity limitsmixedCovered
    linezolid tab 600 mgCoverage Limits: QL (56 tablets/180 days)
    linezolid for susp 100 mg/mlCoverage Limits: QL (600 mls/180 days)
    vancomycin hcl cap 125 mg, 250 mgCoverage Limits: QL (120 capsules/30 days)
    XIFAXAN (rifaximin)200 mg: QL (9 tablets/30 days); 550 mg: QL (126 tablets/365 days)
    Smoking cessation productsmixedCovered
    NICOTINE TRANSDERMAL SYSTEM 21 mg/24hrnicotine patch kit 21-14-7 mg/24hr - Coverage Requirements and Limits = AC, IC
    NICOTROL INHALERnicotine inhaler system 10 mg (4 mg delivered) - Coverage Requirements and Limits = AC, IC
    varenicline tartrate tab 0.5 mg, 1 mgCoverage Requirements and Limits = AC, IC
    Formulary product list (no billing codes in excerpt)mixed
    N/AThis excerpt contains drug product names, strengths, and tier/coverage annotations; no CPT/HCPCS/ICD-10/NDC codes are present in these chunks.
    Selected migraine-related drugs with limitsNDC-like plain names
    ubrogepant tab 50 mg, 100 mgubrogepant tablets listed with PA, QL (16 tablets/30 days)
    dihydroergotamine mesylate inj 1 mg/mLdihydroergotamine mesylate injection — QL (24 ampules/28 days)
    ERGOMAR (ergotamine tartrate sl tab 2 mg)Tier = NP; Coverage Requirements and Limits = PA, QL (20 tablets/28 days)
    REYVOW (lasmiditan succinate tab 50 mg, 100 mg)Coverage Requirements and Limits = QL (8 tablets/30 days) PA
    rizatriptan benzoate tabs and ODT 5 mg, 10 mgCoverage Requirements and Limits = QL (18 tablets/30 days)
    sumatriptan succinate tab 25 mg, 50 mg, 100 mgCoverage Requirements and Limits = QL (18 tablets/30 days)
    Selected antineoplastics / oncology agentsNDC-like plain names
    ABIRATERONE (various strengths)Coverage Requirements and Limits = LD, OC, PA, QL (varies by strength), SP
    lenalidomide (REVLIMID, various strengths)Coverage Requirements and Limits = LD, PA, QL (30 capsules/30 days), SP
    pomalidomide (POMALYST)Coverage Requirements and Limits = LD, OC, PA, QL (21 capsules/28 days); SP
    tazemetostat (TAZVERIK) tab 200 mgCoverage Requirements and Limits = LD, OC, PA, SP
    ALECENSA (alectinib) cap 150 mgCoverage Requirements and Limits = LD, OC, PA, QL (240 capsules/30 days), SP
    Drug list (no CPT/HCPCS/ICD codes present in this extract)mixed
    No codes listed
    Listed Drugs and packaging / quantity limits (partial)NDC/molecule-text
    ripretinib tab 50 mgcoverage: LD OC, PA, QL (90 tablets/30 days), SP
    selpercatinib tab 40 mgcoverage: LD; OC, PA, QL (90 tablets/30 days), SP
    selpercatinib tab 80 mg, 120 mg, 160 mgcoverage: LD, OC, PA, QL (60 tablets/30 days), SP
    vimseltinib cap 14 mg, 20 mg, 30 mgcoverage: LD; OC, PA, QL (8 capsules/28 days), SP
    entrectinib pellet pack 50 mgcoverage: LD, OC, PA, QL (336 pellets/28 days), SP
    entrectinib cap 100 mgcoverage: LD, OC, QL (30 capsules/30 days), SP, PA
    entrectinib cap 200 mgcoverage: LD, OC, (capsules/30 days), SP
    rucaparib camsylate tab 200/250/300 mgcoverage: LD; OC, PA, QL (120 tablets/30 days), SP
    midostaurin cap 25 mgcoverage: OC, PA, QL (240 capsules/30 days), SP
    asciminib hcl tab 20 mg, 40 mg, 100 mgcoverage: various; LD, OC, PA, QL (240 or 120 tablets/30 days), SP
    1–10 of 19
    1/2
    Formulary drug entries and limits (excerpts)mixed
    APRETUDEAPRETUDE (cabotegravir im extended release susp 600 mg/3ml) — Coverage Requirements and Limits = AC, CW, IC
    BIKTARVYBIKTARVY (bictegravir-emtricitabine-tenofovir af tab 30-120-15 mg, 50-200-25 mg) — QL (30 tablets/30 days)
    DOVATODOVATO (dolutegravir sodium-lamivudine tab 50-300 mg) — QL (30 tablets/30 days)
    GENVOYAGENVOYA (elvitegravir-cobicistat-emtricitab-tenofov al tab 150-150-200-10 mg) — QL (30 tablets/30 days)
    ISENTRESSISENTRESS (raltegravir potassium tabs/packets) — CW, IC, QL (varies by formulation: 180 tablets/30 days, 60 packets/30 days, 60 tablets/30 days)
    JULUCAJULUCA (dolutegravir-rilpivirine tab 50-25 mg) — QL (30 tablets/30 days)
    STRIBILDSTRIBILD (elvitegravir-cobicistat-emtricitab-tenofov df tab 150-150-200-300 mg) — QL (30 tablets/30 days)
    ANTIVIRAL COVID AGENTSPAXLOVID and LAGEVRIO entries with QL limits (PAXLOVID QL examples: 11 tablets/30 days; 20 tablets/90 days; 30 tablets/90 days; LAGEVRIO QL 40 capsules/90 days)
    Formulary oral combination agentsmixed
    insulin glargine-lixisenatide sol pen-inj 100-33 unit-mcglmlSOLIQUA 100/33 — QL (18 mls/30 days)
    empagliflozin-metformin hcl tab 5-500 mg; 5-1000 mg; 12.5-500 mg; 12.5-1000 mgSYNJARDY — Tier = P; QL (60 tablets/30 days)
    empagliflozin-metformin hcl tab er 24hr 5-1000 mg, 10-1000 mg, 12.5-1000 mgSYNJARDY XR — Tier = P; QL (60 tablets/30 days)
    empagliflozin-linagliptin-metformin tab er 24hr 5-2.5-1000 mgTRIJARDY XR — Tier = P; QL (60 tablets/30 days)
    Emergency glucagon productsNDC|mixedCovered
    glucagon nasal powder 3 mg/doseBAQSIMI ONE PACK / TWO PACK — Coverage Requirements and Limits = CW
    glucagon subcutaneous solution auto-injector 0.5 mg/0.1ml, 1 mg/0.2mlGVOKE HYPOPEN 1-PACK / 2-PACK — Coverage Requirements and Limits = CW
    dasiglucagon hcl subcutaneous soln auto-inj 0.6 mg/0.6mlZEGALOGUE — Coverage Requirements and Limits = CW
    Insulin products with Illinois Code Compliance and QLmixedCovered
    insulin aspart (with niacinamide) inj 100 unit/mlFIASP — Coverage Requirements and Limits = IC, QL (100 mls/30 days)
    insulin lispro soln cartridge 100 unit/mlHUMALOG — Coverage Requirements and Limits = IC, QL (100 mls/30 days)
    insulin nph (human) inj 100 unit/mlHUMULIN N / NOVOLIN N — Coverage Requirements and Limits = IC, QL (100 mls/30 days)
    insulin glargine-yfgn soln pen-injector 100 unit/mlSEMGL E E / INSULIN GLARGINE-YFGN — Coverage Requirements and Limits = IC, QL (100 mls/30 days)
    Anticoagulants and oral anticoagulant formulationsmixed
    apixaban tab 2.5 mg; apixaban tab 5 mgELIQUIS — QL (74 tablets/19 days or 74 tablets/30 days)
    dabigatran etexilate mesylate cap 75 mg; 150 mgPRADAXA — QL (60 capsules/30 days)
    rivaroxaban for susp 1 mg/ml; rivaroxaban tab 2.5 mg; tab 10 mg; tab 15 mg; tab 20 mgXARELTO — QL values vary by formulation (e.g., 600+ mls/30 days for suspension, 60 tablets/30 days for tablets)
    Oral anticoagulantsmixed
    PRADAXAdabigatran etexilate mesylate pellet pack — QL (60 or 120 packets/30 days depending on listing)
    XARELTOrivaroxaban (susp 1 mg/ml; tabs 2.5 mg, 10 mg, 15 mg, 20 mg) — QL specified including starter pack
    Warfarin (JANTOVEN)warfarin sodium tablets (multiple strengths) — tier p
    Hematopoietic growth factors and supportive oncology biologicsmixed
    ARANESP ALBUMIN FREEdarbepoetin alfa (prefilled syringes and injections) — SP PA flags
    FULPHILApegfilgrastim-jmdb 6 mg prefilled syringe — SP
    HEMLIBRAemicizumab-kxwh subcutaneous solution — LD PA QL (4 vials/28 days) SP
    Thrombopoietin receptor agonistsmixed
    PROMACTA / eltrombopageltrombopag powder for suspension and tablets — PA, QL, LD, SP noted
    MULPLETAlusutrombopag tab 3 mg — PA, QL, SP
    Coagulation factors and hemostasis productsmixed
    ADVATEantihemophilic factor recombinant — LD PA QL (1 ml/30 days) SP
    ALPHANATEantihemophilic factor/vWF (human) — LD PA QL (1 ml/30 days) SP
    ALPROLIXcoagulation factor IX recombinant — LD QL (1 vial/30 days) SP PA
    COAGADEXcoagulation factor X (human) — LD SP
    ELOCTATEantihemophilic factor recombinant — LD PA QL (1 vial/30 days) SP
    FIBRYGA / RIASTAPfibrinogen concentrate (human) — LD SP
    HEMLIBRA (additional listings)emicizumab with QL (4 pens/28 days) SP
    Platelet modifying agents / aspirinmixedCovered
    aspirin 81 mg (chewable, delayed release, various brands)low-dose aspirin products — Tier p, Coverage Requirements = AC, IC
    aspirin-dipyridamole 25-200 mg ERcombined agent — tier and coverage presented
    Prior authorization validity / maintenance medication PA validity
    PA validity (standard)Prior authorization approvals are valid for the lesser of six months or the length of treatment determined by the prescribing provider.
    PA validity (maintenance meds)For maintenance medications to treat chronic/long-term conditions, PA approvals are valid for the lesser of 12 months or the length of treatment determined by the prescribing provider.
    PA deemed granted timingIf BCBSIL does not respond to a non-urgent PA within 72 hours (or an urgent PA within 24 hours) using the uniform electronic PA form, the request is deemed granted.
    Retail/home delivery supply length — 30- and 90-day supply rules
    Standard retail supplyParticipating retail pharmacies: prescriptions may be filled for up to a 30-day supply (with some exceptions).
    Maintenance medication supply (retail/home delivery)Some plans provide coverage for up to a 90-day supply of maintenance medications at select retail pharmacies or via home delivery; verify plan-specific benefits.
    Home delivery benefit noteHome delivery can provide a 90-day supply of maintenance drugs delivered within the U.S.; check MyPrime.com or bcbsil.com for network/home delivery details.
    Examples of Quantity Limits
    High-volume oral liquid (acetaminophen-codeine)Acetaminophen–codeine oral solution (120–12 mg/mL): QL = 2700 mL per 30 days.
    Butorphanol nasal solution strength and limitButorphanol tartrate nasal solution 10 mg/mL (10 mg/mL): QL = 5 mL per 30 days.
    Lidocaine topical productsLidocaine ointment 5%: QL = 120 grams/30 days; Lidocaine patch 5%: PA required and QL = 120 patches/30 days.
    Specialty inhaled antibacterial (ARIKAYCE)ARIKAYCE (amikacin liposome inhalation) 590 mg/8.4 mL: QL = 235.2 mL per 28 days; designated LD, PA, SP.
    100 mcg/hr transdermal patch100 mcg/hr patch presentation: QL = 15 patches per 30 days.

    Provider Responsibilities and Operational Guidance

    Prior Authorization

    Obtain prior authorization for drugs marked “PA”

    Certain medications listed on the formulary require prior authorization (PA); when a drug line shows “PA” in the Coverage Requirements and Limits column the provider must obtain an approved prior authorization before the medication will be covered. A PA approval is valid for the lesser of six months or the length of treatment (maintenance meds: lesser of 12 months or length of treatment).

    • PA appears next to drugs in the Coverage Requirements and Limits column; obtain PA before dispensing when shown.
    • PA validity: lesser of 6 months or length of treatment; maintenance meds: lesser of 12 months or length of treatment.
    Prior Authorization

    Review monthly UM changes (PA/QL updates)

    This month’s monthly change chart includes utilization management updates — for example CTEXLI (chenodiol) had PA and a QL added and several ondansetron/granisetron strengths had QL removals; providers should review the monthly change chart for added PA/QL changes that may affect current prescriptions.

    • CTEXLI (chenodiol 250 mg) — UM change: PA and QL added.
    • Selected ondansetron and granisetron strengths — UM change: QL removed.
    • BCBSIL updates the drug list monthly; check the chart for current PA/QL changes.
    Note

    New specialty/high-tier drugs assigned Tier 3 or Tier 4

    Numerous newly added specialty or high-tier drugs were assigned Tier 3 or Tier 4 (examples include GOMEKLI, OMVOH, SPEVIGO, TRYNGOLZA); expect these products to carry specialty handling and potential utilization controls.

    • GOMEKLI additions show New Tier = Tier 4.
    • OMVOH and other biologics added with Tier 3 or Tier 4 assignments.
    • Tier increases may affect member cost share and prior authorization expectations.
    Prior Authorization

    Obtain PA for listed topical lidocaine products

    Selected topical lidocaine products list PA and QL on their drug lines (e.g., Lidocaine Ointment 5% = PA, QL 120 g/30 days; Lidocaine Patch 5% = PA, QL 120 patches/30 days); obtain prior authorization and document expected days’ supply before dispensing.

    • Lidocaine Oint 5% — Coverage Requirements and Limits = PA, QL (120 grams/30 days).
    • Lidocaine Patch 5% — Coverage Requirements and Limits = PA, QL (120 patches/30 days).
    Prior Authorization

    PA required for selected specialty/high-cost agents

    Several specialty or high-cost agents are annotated with PA (examples: ARIKAYCE — LD, PA, QL; TOBI PODHALER — PA, QL; EPIDIOLEX and FINTEPLA entries also show PA); providers must obtain prior authorization for these agents prior to coverage and follow limited distribution/specialty channel requirements where indicated.

    • ARIKAYCE — Coverage Requirements and Limits = LD, PA, QL (235.2 mls/28 days).
    • TOBI PODHALER — Coverage Requirements and Limits = PA, QL (224 capsules/56 days).
    • EPIDIOLEX/FINTEPLA and other high-cost agents are listed with PA in formulary excerpts.
    Prior Authorization

    PA required for ER/sprinkle formulations labeled “PA”

    Extended‑release, ER, or sprinkle formulations shown with “PA” on the formulary require prior authorization before coverage; review each product line for PA and supporting documentation when dispensing these formulations.

    • Topiramate ER sprinkle formulations and other ER/sprinkle products are listed with PA and QL where applicable.
    • Follow PA program and submit required documentation for ER/sprinkle formulations flagged PA.
    Prior Authorization

    Obtain PA for listed antifungals and migraine biologics

    Selected antifungals and migraine agents require prior authorization per their formulary entries (e.g., CRESEMBA is listed with PA; migraine biologics such as AIMOVIG/EMGALITY/AJOVY require PA and have QL limits).

    • CRESEMBA (isavuconazonium) — Coverage Requirements and Limits = PA.
    • AIMOVIG, AJOVY, EMGALITY — Coverage Requirements and Limits include PA and product-specific QL (for example AIMOVIG PA, QL 1 injection/28 days).
    Prior Authorization

    Obtain PA when “PA” appears next to product

    Multiple formulary entries include a “PA” indicator; providers must obtain prior authorization for those drugs prior to coverage — check each drug line for the PA flag and submit PA documentation accordingly.

    • When a drug line shows PA, prior authorization is a coverage prerequisite.
    • Submit required clinical documentation as described in the PA program.
    Documentation Required

    Submit PA + clinical documentation for PA‑flagged products

    When PA is indicated on a drug line (common for many oral oncology and specialty medications), providers must submit a prior authorization request and supporting clinical documentation to secure coverage; limited distribution products may also require specialty channel fulfillment.

    • Oral oncology entries frequently list LD and PA — use designated specialty channels and submit PA.
    • Provide indication, dosing, and prior therapy documentation to support PA requests.
    Denial Risk

    PA required where PA flag is shown — claims may be denied without it

    If a drug’s Coverage Requirements list PA, providers must obtain prior authorization before dispensing; failure to secure an approved PA may result in claim denial for that agent.

    • Coverage flags such as PA denote programmatic controls that must be satisfied for coverage.
    • Claims for PA‑designated drugs may be denied without an approved PA.
    Prior Authorization

    Obtain PA for GLP‑1/tirzepatide agents where shown

    Examples in the GLP‑1/tirzepatide class show prior authorization requirements (MOUNJARO, OZEMPIC, TRULICITY are listed with PA and specific quantity limits); obtain PA and observe QL when prescribing these agents.

    • MOUNJARO — Coverage Requirements and Limits = PA, QL (4 pens/28 days or 180 days per presentation).
    • OZEMPIC — Coverage Requirements and Limits = PA, QL (1–3 pens/28 days depending on presentation).
    • TRULICITY — Coverage Requirements and Limits = PA, QL (4 pens/28 days).
    Prior Authorization

    TRULICITY (and select GLP‑1s) require prior authorization

    Prior authorization is required for select GLP‑1 agents such as TRULICITY which is listed with Coverage Requirements = PA and QL (4 pens/28 days); submit PA and include documentation supporting indication and dosing.

    • TRULICITY — PA required; QL = 4 pens/28 days.
    • Provide clinical rationale and prior therapy details when requesting PA.
    Prior Authorization

    PA required for selected hematopoietic and coagulation agents

    Many hematopoietic growth factors, pegfilgrastim biosimilars, darbepoetin products and related supportive agents are designated PA (and often SP/LD); obtain prior authorization and adhere to listed quantity limits when requesting coverage.

    • ARANESP/pegfilgrastim biosimilars — SP/PA designations present.
    • HEMLIBRA — Coverage Requirements and Limits = LD, PA, QL (4 vials/28 days) for some listings.
    Note
    Step Therapy

    Follow step therapy (ST) when indicated; exceptions may be requested

    Some drugs on the formulary are subject to step therapy (ST); where “ST” appears in the Coverage Requirements and Limits column providers should follow the step program and may request an exception if clinical criteria are met.

    • ST is indicated in the formulary key — follow product‑specific step therapy requirements when shown.
    • Providers may request step therapy exceptions; BCBSIL reviews exceptions per program rules.
    Note

    Check monthly updates for new utilization review restrictions

    The formulary is updated monthly and may introduce new utilization review (UR) restrictions including PA and QL; providers should check the monthly change chart to confirm whether new UR controls apply to a prescribed drug.

    • Monthly change chart lists additions, tier moves, and new UM restrictions.
    • BCBSIL provides at least 60 days’ notice for tier increases, exclusions, or stricter UR for affected members.
    Step Therapy

    Step therapy flags present — consult product lines for specifics

    The drug list key includes ST (Step Therapy) flags; specific step therapy rules are not detailed in this excerpt, so providers must refer to each product line or the full formulary for applicable step sequences and requirements.

    • KEY shows ST = Step Therapy; product rows with ST apply step requirements.
    • When ST appears next to a drug, follow the listed step program in the full formulary.
    Step Therapy

    Adhere to step therapy for agents marked “ST” (e.g., FETZIMA, TRINTELLIX)

    Step therapy is defined in the formulary key and applies where “ST” appears next to specific drugs (examples in the extract: FETZIMA and TRINTELLIX show ST); follow the product‑specific ST requirements for those agents.

    • FETZIMA (levomilnacipran) — Coverage Requirements and Limits = ST.
    • TRINTELLIX (vortioxetine) — Coverage Requirements and Limits = ST.
    Step Therapy

    ST flagged entries — seek full formulary for step sequences

    Some formulary entries include an ST indicator but the excerpt does not show explicit step therapy chains; providers must consult the full formulary or product‑level rules for required prior agents and exception procedures.

    • ST appears in the KEY but step sequences are not shown in these chunks.
    • Use the full drug list/product entry to determine required prior therapies.
    Step Therapy

    Observe step therapy indicators where present

    Agents marked with “ST” in the key or next to the drug require adherence to step therapy when applicable; specific ST instructions are provided on the individual drug lines elsewhere in the formulary.

    • Presence of ST in the key indicates step therapy may apply to some items.
    • Follow product-specific ST entries in the full formulary for enforcement.
    Step Therapy

    Step therapy applies to selected antidepressants (FETZIMA, TRINTELLIX)

    FETZIMA (levomilnacipran) and TRINTELLIX (vortioxetine) are listed with Step Therapy (ST) in their Coverage Requirements and Limits; follow ST program requirements and documentation processes when prescribing these antidepressants.

    • FETZIMA — Coverage Requirements and Limits = ST.
    • TRINTELLIX — Coverage Requirements and Limits = ST.
    Documentation Required

    Submit exceptions when clinically appropriate for ST-flagged drugs

    Where the formulary indicates “ST” for a product, providers must abide by the step therapy protocol in the full formulary; this excerpt notes ST presence but not the detailed chains — request a step therapy exception if clinically justified.

    • ST is indicated in the KEY; product-specific ST rules appear in full drug entries.
    • Exception requests may be submitted and will be adjudicated per BCBSIL rules.
    Note

    ST is noted in key — consult product entries for step details

    The formulary key shows ST flags but does not include specific step sequences in this excerpt; providers must check individual drug listings or the full formulary for any required prior steps.

    • ST appears in the KEY; consult the product line for step details.
    • Monthly updates may add ST requirements for specific drugs.
    Step Therapy

    Follow ST requirements for products annotated ST (e.g., risperidone ODT)

    Some products are marked with the step therapy flag (ST) in the KEY (examples: risperidone ODT shows QL and ST); observe ST where shown and provide documentation of prior therapy or medical rationale if requesting an exception.

    • Risperidone ODT — Coverage Requirements and Limits = QL (60 tablets/30 days), ST.
    • When ST is present, include prior therapy records or rationale with exception requests.
    Note
    Note
    Note
    Documentation Required

    Submit PA requests via BCBSIL provider forms or phone

    When the formulary indicates PA for a product, providers must submit prior authorization requests using BCBSIL forms available at bcbsil.com/provider or by calling the number on the member ID card.

    • PA forms and submission instructions available at bcbsil.com/provider or via the phone number on the member ID card.
    • For expedited or standard exception/PA processing timelines see the Exception Process section.
    Documentation Required

    Use copay waiver / coverage exception forms on bcbsil.com or myprime.com

    Copay waiver and coverage exception forms (including for ACA preventive or No‑Cost Preventive Drug List items) are available at bcbsil.com/provider or myprime.com; use these forms when requesting a copay waiver or coverage exception.

    • Copay waiver and coverage exception forms are on bcbsil.com/provider and myprime.com.
    • Follow the ACA preventive guidance when submitting copay waiver requests.
    Documentation Required

    Submit coverage exceptions — decision timelines (72 hrs standard, 24 hrs expedited)

    Coverage exception requests may be submitted by the member, prescriber, or authorized representative; BCBSIL will notify the decision within 72 hours for standard requests or within 24 hours for expedited (urgent) requests.

    • Standard exception decision timeframe = 72 hours.
    • Expedited (urgent) exception decision timeframe = 24 hours.
    Billing Rule

    Adhere to dispensing QLs for analgesics/NSAIDs when billing

    Selected analgesics and NSAIDs include explicit quantity limits (QL) that must be followed when submitting pharmacy claims (e.g., celecoxib 50/100/200 mg = QL 60 caps/30 days; ketorolac 10 mg = QL 20 tablets/30 days); ensure days‑supply and quantity conform to QL.

    • Celecoxib 50/100/200 mg — QL 60 capsules/30 days; celecoxib 400 mg — QL 30 capsules/30 days.
    • Ketorolac tromethamine 10 mg — QL 20 tablets/30 days.
    Documentation Required

    Document dispensing for CW (cost‑waived) opioid reversal agents

    Certain opioid reversal agents are designated CW (Cost Waived) under Illinois mandate (e.g., naloxone nasal sprays, prefilled syringes); documentation of dispensing may be required per program rules to support cost‑waived handling.

    • Naloxone nasal sprays and prefilled syringes appear with Coverage Requirements and Limits = CW.
    • Pharmacies should document dispensing per program guidance to support cost‑waived coverage.
    Documentation Required

    Provide documentation supporting dispensed quantity vs. listed QL

    Quantity limits (QL) are specified for many formulary agents (e.g., ARIKAYCE QL 235.2 mL/28 days, TOBI PODHALER QL 224 capsules/56 days); include expected days‑supply or units in documentation to support dispensing when requesting authorization for quantities near the QL.

    • ARIKAYCE — QL 235.2 mL/28 days.
    • TOBI PODHALER — QL 224 capsules/56 days.
    • Linezolid tab 600 mg — QL 56 tablets/180 days.
    Documentation Required

    Include clinical documentation to support PA and QL requests

    For drugs flagged PA or QL, providers must include documentation that supports medically necessary dosing and indication when submitting prior authorization or exception requests to avoid denial.

    • Include diagnosis, prior therapies, and dose/days‑supply justification with PA requests.
    • Documentation expectations apply to formulations noted with PA or QL.
    Prior Authorization

    PA and QL for migraine biologics (AIMOVIG, EMGALITY, etc.)

    Certain migraine biologics require PA and have explicit quantity limits (e.g., AIMOVIG = PA, QL 1 injection/28 days; EMGALITY = PA, QL varies by presentation); obtain PA and follow QL when prescribing these agents.

    • AIMOVIG — Coverage Requirements and Limits = PA, QL (1 injection/28 days).
    • EMGALITY — Coverage Requirements and Limits = PA, QL (1 syringe/28 days or 9 syringes/180 days per presentation).
    Billing Rule

    Use specialty/limited distribution channels and obtain PA for LD/OC drugs

    For drugs designated LD (Limited Distribution) or OC (Oral Cancer Medications), providers may need to use specified specialty channels or limited distribution pharmacies and must obtain prior authorization when indicated.

    • LD and OC designations frequently accompany PA and QL flags for oncology agents.
    • Use required specialty distribution channels for LD products to secure fulfillment and coverage.
    Documentation Required

    Provide indication and prior‑therapy documentation with PA requests

    When a drug line lists PA, prescribers must submit supporting documentation (indication, dosing, prior therapies) with the prior authorization request to substantiate medical necessity and secure coverage.

    • Provide indication, prior therapy history, and dosing schedule with PA submissions.
    • PA program requirements and forms available on the BCBSIL provider site.
    Billing Rule

    Adhere to product QLs (e.g., insulin 100 mL/30 days) to avoid member liability

    Ensure dispensing aligns with the product‑specific quantity limits (QL) listed on the formulary (e.g., many insulins QL 100 mL/30 days; SYNJARDY QL 60 tablets/30 days); dispensing beyond QL may require prior authorization or result in member financial liability.

    • Insulins (FIASP, HUMALOG, HUMULIN N) — Coverage Requirements and Limits = IC, QL (100 mL/30 days).
    • SYNJARDY/SYNJARDY XR — QL 60 tablets/30 days.
    • Exceeding QL may leave the member responsible for full cost of excess quantity.
    Denial Risk

    Dispensing beyond QL may leave member financially responsible

    If the dispensed quantity exceeds the plan's dispensing limit, the member may be responsible for the full cost of the prescription beyond what coverage allows; verify QL before dispensing and obtain PA if an exception is clinically required.

    • Dispensed quantity beyond QL may result in no benefits applied for the excess.
    • Obtain PA or coverage exception to mitigate member financial exposure when clinically necessary.
    Denial Risk

    Claims may be denied without required prior authorization

    Claims for medications listed with a PA flag may be denied if an approved prior authorization is not in place; verify PA requirements at point of prescribing/dispensing and submit PA in advance to avoid denial.

    • PA indicated on drug lines must be obtained prior to dispensing to secure coverage.
    • Lack of PA when required can trigger claim denial.
    Note

    UM changes (QL removals/additions) may affect authorization

    UM changes this cycle included QL removals for select ondansetron and granisetron strengths and QL additions for nilotinib 200 mg; these changes can affect authorization and coverage for affected strengths — confirm current QL before fulfilling prescriptions.

    • Granisetron HCl 1 mg — UM change: QL Removed.
    • Nilotinib HCl cap 200 mg — UM change: QL Added.
    Denial Risk

    PA required for topical products flagged PA (denial risk if not obtained)

    Topical products flagged PA (e.g., Lidocaine Oint 5%) require prior authorization; dispensing without PA when PA is indicated may result in denial of coverage for that product.

    • Lidocaine Oint 5% — PA and QL listed; obtain PA before dispensing.
    • Lack of PA for PA‑flagged topical products can trigger denial.
    Billing Rule

    Verify PA at point of dispensing for PA‑flagged drugs

    Products flagged PA at the point of dispensing will require an approved prior authorization; ensure the pharmacy point‑of‑sale has a valid PA to prevent claim rejection or denial.

    • PA is enforced at dispensing when flagged on the drug line.
    • Verify PA status at point of sale to avoid denial.
    Billing Rule

    Use required specialty/limited distribution channels for LD/SP drugs

    Limited Distribution (LD) and Specialty (SP) designations indicate specific handling and distribution channels; if the required specialty channel or LD process is not followed the product may not be fulfillable or covered.

    • LD/ SP products (e.g., ARIKAYCE) require specialty fulfillment and associated PA/QL.
    • Follow specialty vendor/LD instructions to secure coverage and delivery.
    Denial Risk

    PA/QL flags are potential denial triggers — confirm before dispensing

    Formulations or products marked with PA or with specific QL are potential denial triggers if requirements are not met; review each drug line for PA/QL prior to dispensing to avoid denials.

    • PA or QL flags on the formulary indicate administrative controls that must be satisfied.
    • Noncompliance with PA/QL can result in claim denial or member financial responsibility.
    Prior Authorization

    PA required for selected antifungals (e.g., CRESEMBA, posaconazole)

    Certain antifungal agents (e.g., CRESEMBA, posaconazole) are listed with PA; claims for these products may be denied without an approved prior authorization — obtain PA and submit required clinical documentation prior to dispensing.

    • CRESEMBA (isavuconazonium) — Coverage Requirements and Limits = PA.
    • Posaconazole (susp and delayed release tabs) — Coverage Requirements and Limits = PA.
    Denial Risk

    Obtain PA for PA‑designated drugs to avoid denial

    Claims for medications listed with “PA” may be denied or require prior authorization review if an authorization is not obtained; verify PA requirements and obtain authorizations before dispensing these agents.

    • Many oncology and specialty agents list PA — obtain authorization to prevent denial.
    • PA absence on submission can trigger coverage denial.
    Denial Risk

    PA required for oral oncology/specialty agents — risk of denial if not obtained

    Failure to obtain prior authorization for oral oncology and many specialty agents marked PA may trigger coverage denial; submit PA requests with required supporting documentation to avoid claim denial.

    • Oral oncology agents commonly show LD, OC, PA, QL — submit PA and use LD channels.
    • Provide full clinical documentation to support medical necessity for PA.
    Denial Risk

    Confirm PA presence — absence may cause claim denial

    Lack of an approved prior authorization when PA is listed for an agent may trigger claim denial; confirm PA status and secure approvals before dispensing PA‑flagged medications.

    • Verify PA prior to dispensing to avoid claim denial.
    • Submit PA with indication and dosing details as required.
    Denial Risk

    Coverage flags (PA/CW/IC/QL/ST/LD/SP) must be satisfied to avoid denial

    Coverage codes and flags on drug lines (PA, CW, AC, IC, QL, ST, SP, LD) indicate programmatic controls; failure to meet any applicable control (for example not obtaining PA or exceeding QL) can trigger denial or member financial liability.

    • PA — Prior Authorization required when shown.
    • QL — Quantity Limit; exceeding QL may make member responsible for excess.
    • IC/CW/LD/SP — State or distribution special handling that must be followed.
    Documentation Required

    PA/CW designations for select GLP‑1/tirzepatide/glucagon products

    Some GLP‑1 and tirzepatide products are designated PA or CW (e.g., MOUNJARO, OZEMPIC, TRULICITY); obtain PA where indicated and provide documentation for cost‑waived (CW) status when applicable to ensure coverage.

    • MOUNJARO/OZEMPIC/TRULICITY show PA and product‑specific QL.
    • Some glucagon/glucagon‑related products show CW — documentation may be needed for cost‑waived handling.
    Prior Authorization

    PA plus Limited Distribution — obtain PA and use LD channel

    Products listed with both PA and LD flags require prior authorization and may need specific limited distribution arrangements; lacking either may prevent coverage or fulfillment — coordinate PA and required specialty channel routing.

    • LD products (many oncology and some inhaled antibacterials) also list PA and QL.
    • Work with specialty pharmacies or LD distributors as directed in product entries.
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Key and Definitions

    Formulary / Drug Tier / Prior Authorization / Step Therapy definitions
    FormularyThe formulary (drug list) is the complete list of drugs preferred for use and eligible for coverage under the outpatient pharmacy benefit.
    Drug TierDrug Tier groups drugs into cost-sharing categories that determine member out-of-pocket responsibility (e.g., Preferred Generic, Non-Preferred Generic, Preferred Brand, Non-Preferred Brand).
    Prior Authorization & Step TherapyPrior Authorization (PA) requires issuer approval before coverage; Step Therapy (ST) specifies an appropriate sequence of medications that may be required prior to covering a given drug, with exception processes available.
    Specialty drugs definition
    Specialty drugs — scopeDrugs used to treat complex conditions (e.g., hepatitis, hemophilia, multiple sclerosis, rheumatoid arthritis); may be oral, topical, or injectable and can be self-administered or administered by a health care professional.
    Specialty channel noteSome specialty drugs require specialty pharmacy handling or limited distribution channels; medications administered by a health care professional are not covered under the pharmacy benefit.
    List accessA current list of specialty medications is available at myprime.com or bcbsil.com (Blue Access for Members).
    Dispensing Limits (QL/DL) definition
    Definition of Dispensing Limits (DL/QL)Dispensing Limits/Quantity Limits restrict quantity per prescription or within a time period to encourage FDA-intended use; exceeding limits may leave the member responsible for full cost beyond allowed coverage.
    How limits presentedIf a dispensing limit applies it will be noted as 'QL' in the Coverage Requirements and Limits column for the medication.
    State law impactSome state laws may prohibit coverage of controlled substances dispensed beyond dispensing limits; in such cases the member is responsible for full cost if limits are exceeded.
    Coverage designators — CW/IC/OC/ACA etc.
    Coverage designators (overview)Coverage flags used on the formulary include: CW (Cost Waived), IC (Illinois Code Compliance), OC (Oral Cancer medications), AC (ACA Preventive), PA (Prior Authorization), QL (Quantity Limits), ST (Step Therapy), SP (Specialty), LD (Limited Distribution).
    Effect on cost-sharingDesignators like CW, IC, and AC may indicate limited or $0 member cost-sharing when conditions are met; verify plan-specific details.
    Operational impactPresence of PA, QL, LD, or SP implies administrative or distribution requirements (e.g., PA must be obtained when indicated; LD/SP may require designated specialty channels).
    Formulary Key Definitions — QL/PA/ST/SP/LD etc.
    QL = Quantity/Dispensing LimitsQL indicates Dispensing Limits/Quantity Limits restricting quantity per time period for coverage.
    PA = Prior AuthorizationPA indicates the drug requires prior authorization before coverage is provided.
    ST / SP / LDST = Step Therapy; SP = Specialty (specialty pharmacy handling); LD = Limited Distribution (restricted distribution channel).
    QL definition
    QL termQL = Dispensing Limits / Quantity Limits (notation used in Coverage Requirements and Limits column).
    PurposeUsed to limit quantity per prescription or time period to encourage FDA-intended use.
    NotationListed next to product as 'QL (amount/period)' on product rows.
    PA definition
    PA termPA = Prior Authorization — issuer authorization required before coverage; noted as 'PA' in the Coverage Requirements and Limits column.
    Provider actionPrescribers must submit PA requests using forms on bcbsil.com/provider or by calling the number on the member ID card.
    Validity rulesPA approvals are valid per PA validity rules (typically lesser of 6 months or length of treatment; maintenance meds: lesser of 12 months or length of treatment).
    CW definition
    CW termCW = Cost Waived — indicates medicines mandated by Illinois or plan rules to have $0 member cost-sharing when conditions are met.
    ExamplesNaloxone formulations (e.g., nasal sprays, prefilled syringes) are designated CW in the formulary listings.
    Plan variationCoverage and applicability of CW designator may vary by benefit plan; verify with member's plan materials.
    PA = Prior Authorization (from key)
    PA acronymPA = Prior Authorization (as shown in the formulary key).
    UsageAppears in Coverage Requirements and Limits column to indicate PA requirement on product rows.
    Action requiredObtain PA prior to dispensing to avoid coverage denial when PA is indicated.
    QL = Dispensing Limits / Quantity Limits (from key)
    QL acronymQL = Dispensing Limits / Quantity Limits (as shown in the formulary key).
    InterpretationSpecifies maximum quantity permitted per stated time period (e.g., 'QL (60 tablets/30 days)').
    ConsequenceDispensing beyond QL may result in member financial responsibility for excess quantity.
    LD = Limited Distribution (from key)
    LD acronymLD = Limited Distribution — product is distributed through a restricted channel or specific specialty pharmacy.
    ImplicationLD designations often accompany PA and SP flags and may require use of designated distribution channels to obtain coverage.
    ExamplesSelected antineoplastics and inhaled antibacterials (e.g., ARIKAYCE, KITABIS PAK) list LD in product rows.
    SP = Specialty (from key)
    SP acronymSP = Specialty — indicates specialty pharmacy handling for certain high-cost or complex therapies.
    Distribution requirementSP products may require fulfillment via specialty pharmacy channels and often carry PA and QL requirements.
    Typical classesIncludes many oncology, hemophilia/coagulation, and biologic therapies listed as SP in the formulary.
    AC = ACA Preventive (from key)
    AC acronymAC = ACA Preventive — medications listed under Affordable Care Act preventive coverage provisions and may have limited or $0 member cost-sharing when conditions are met.
    How to requestCopay waiver and coverage exception forms for ACA preventive medicines are available at bcbsil.com/provider or myprime.com; verify eligibility per plan.
    Plan specificsCoverage and applicability of ACA preventive designation may vary by benefit plan and may be subject to member deductible for some HDHPs.
    PA (repeated definition instances)
    PA (repeated) — shortPA = Prior Authorization — issuer approval required before coverage is provided when noted.
    ReferenceShown repeatedly in the formulary key and product rows to indicate PA requirements.
    Provider actionSubmit PA requests via bcbsil.com/provider or call the number on the member ID card.
    QL (repeated definition instances)
    QL (repeated) — shortQL = Dispensing Limits / Quantity Limits — maximum quantity per time period noted on product rows.
    Displayed formatTypically shown as 'QL (amount/unit per period)' next to the product listing.
    EnforcementDispensing beyond QL may result in no coverage for the excess quantity.
    LD (repeated definition instances)
    LD (repeated) — shortLD = Limited Distribution — restricted distribution channel noted on product rows.
    Common pairingFrequently paired with OC, PA, and SP designators for oncology and specialty agents.
    Access implicationMay require use of a specific specialty pharmacy to obtain product under the benefit.
    PA (repeated)
    PA (repeated) — conciseWhen 'PA' appears in Coverage Requirements and Limits, prior authorization is required for coverage of that drug.
    Product examplesPA appears across many product lines (e.g., oncology oral agents, specialty inhaled antibacterials, selected GLP-1 agents).
    Provider responsibilityProviders must submit PA with supporting clinical documentation when PA is indicated to avoid denials.
    QL (repeated)
    QL (repeated) — conciseQL flags specify dispensing/quantity limits (e.g., QL (30 tablets/30 days)); these are enforced at claim adjudication.
    ExamplesMany entries list QL values per product or formulation (see product rows for exact amounts).
    RiskExceeding QL may result in member financial responsibility for the excess quantity or claim denial.
    LD (repeated)
    LD (repeated) — conciseLD indicates limited distribution requiring specified channels; often used for high-cost oncology or specialty agents.
    Operational noteLD listings commonly include PA and SP flags and explicit QL values.
    ExamplesSelected antineoplastics (e.g., abiraterone, lenalidomide) and inhaled antibacterials show LD in product rows.
    OC (repeated)
    OC (repeated) — conciseOC = Oral Cancer Medications — oral cancer drugs that have analogous guidelines to physician-administered cancer medications and may limit member cost-sharing.
    Typical flagsOC products frequently carry LD, PA, QL, and SP designators in the formulary listings.
    Member cost-shareOC designation may cap member cost-sharing; check benefit plan for details.
    SP (repeated)
    SP (repeated) — conciseSP = Specialty — indicates specialty pharmacy handling and often accompanies PA, LD, and QL requirements.
    DistributionSP products typically require specialty fulfillment and additional documentation at point of dispensing.
    ExamplesMany coagulation factors, biologics, and oncology agents are listed as SP.
    LD (repeated)
    LD (repeated) — additional noteLD flag appears repeatedly in oncology and specialty listings indicating restricted supply chains for these products.
    Fulfillment impactCoverage may depend on using the designated limited distribution pharmacy; failure to use required channel may prevent fulfillment.
    Related flagsLD commonly shown with OC, PA and SP on product rows.
    OC (repeated)
    OC (repeated) — additional noteOC appears alongside LD and PA for many oral oncology agents, indicating special handling and cost-share rules.
    Coverage guidanceOral cancer medications follow similar guidelines as injectable/physician-administered cancer therapies; see product rows for QL and PA requirements.
    Verify plan detailsMember cost-sharing and coverage conditions for OC products vary by plan — check benefit materials.
    PA (repeated)
    PA (repeated) — enforcementPA marked on product lines requires prior authorization before coverage; claims without required PA may be denied.
    Submission pathwayProviders may submit PA forms via bcbsil.com/provider or call the number on the member ID card to initiate authorization requests.
    Deemed grant rulesIf issuer does not respond within prescribed timeframes (72/24 hours), requests may be deemed granted per PA rules.
    QL (repeated)
    QL (repeated) — product notationQL notation indicates precise dispensing limits (e.g., 'QL (60 capsules/30 days)'); follow product rows for exact amounts.
    Coverage consequenceDispensing in excess of QL can result in no coverage for the excess quantity and member financial liability.
    DocumentationProviders should document medically necessary dosing and indication when requesting exceptions to QL.
    SP (repeated)
    SP (repeated) — product contextSP designation repeatedly signals specialty handling for listed products (e.g., ARIKAYCE, TOBI PODHALER).
    Associated requirementsSP items commonly carry PA and QL restrictions and may require specialty pharmacy fulfillment.
    Where listedSP appears in the formulary key and next to many specialty product entries throughout the drug list.
    LD (repeated)
    LD (repeated) — product examplesLD flags appear on inhaled antibacterials and many oncology agents (e.g., KITABIS PAK, ARIKAYCE, select oral oncologics).
    Access noteLimited distribution products may only be available through designated channels; coverage may depend on adherence to those channels.
    Common pairingLD is frequently paired with PA and SP in product listings.
    OC (repeated)
    OC (repeated) — enforcementOC designation carries special cost-sharing and handling rules; many OC products are LD/PA/SP-labeled.
    Provider actionObtain PA and follow limited distribution/specialty channel requirements where noted to secure coverage for OC drugs.
    Plan verificationCheck member's benefit plan for OC cost-sharing protections and limitations.
    PA (repeated)
    PA (repeated) — summaryPA entries instruct that prior authorization is required before coverage when shown; approvals have defined validity periods (6 months or maintenance rules apply).
    Exception processMembers or prescribers may request exceptions; BCBSIL will notify decisions per established timeframes (72/24 hours).
    Where to find formsPA forms and submission instructions available at bcbsil.com/provider or via the contact number on the member ID card.
    QL (repeated)
    QL (repeated) — reminderQL is used throughout product rows to denote maximum covered quantities per specified time period; see each product line for exact QL values.
    Impact on claimsClaims exceeding QL may be denied or result in member responsibility for excess medication costs.
    Exception requestsProviders can request exceptions to QL; supporting clinical documentation is typically required.
    SP (repeated)
    SP (repeated) — conciseSP denotes Specialty handling; specialty products often require PA, have QL, and may be LD.
    Distribution implicationSpecialty items are processed via specialty pharmacies with associated administrative requirements.
    ExamplesCoagulation factors, pegfilgrastim products, and many oncology agents are listed as SP.
    QL (repeated)
    QL (repeated) — enforcement noteQL notations set the allowed dispensing quantity (e.g., 30/30, 60/30, 120/30); adherence is required to maintain coverage.
    Interaction with LD/SPLD or SP designations often accompany QL limits for specialty products; follow both quantity and distribution requirements.
    Member financial riskDispensing beyond QL can leave the member liable for full cost of the excess amount.
    IC (Illinois Code Compliance) definition
    IC definitionIC = Illinois Code Compliance — indicates products regulated under the Illinois Insurance Code and that may have limited or $0 member cost-sharing when conditions are met.
    Typical applicationMany insulin products are listed with IC plus QL (100 mL/30 days) to reflect Illinois-specific requirements.
    Verify plan detailsIC applicability and member cost-sharing depend on the member's benefit plan — confirm via plan materials.
    CW definition
    ExamplesEmergency glucagon kits and many naloxone formulations are shown as CW in the formulary.
    Plan variationAvailability of CW status can vary by benefit plan; check member-specific coverage for applicability.
    CW (repeated)
    CW repeatedCW appears repeatedly in the formulary key to indicate cost-waived products (e.g., naloxone, glucagon emergency products).
    Operational noteCW items may still require pharmacy documentation or specific dispensing processes per program rules.
    Where shownCW is listed in the Coverage Requirements and Limits column for qualifying products.
    IC (repeated)
    IC repeatedIC is repeated across insulin and other product listings to flag Illinois Code Compliance requirements and potential $0 cost-sharing under regulation.
    Common associated QLIC entries commonly pair with QL specifications (e.g., 100 mL/30 days for many insulins).
    Plan verificationConfirm IC-related coverage and cost-sharing applicability in the member's benefit plan materials.
    QL (repeated)
    QL (repeated) — short noteQL indicates quantity limits shown next to products (e.g., QL (30 tablets/30 days)); repeated throughout the formulary.
    Provider actionEnsure dispensing aligns with QL or obtain PA/exception to cover quantities beyond QL.
    Member riskExceeding QL can result in member financial responsibility for excess quantity.
    PA (repeated)
    PA (repeated) — enforcement reminderPA required where indicated; lack of PA may result in claim denial. Obtain PA per formulary instructions.
    Submission resourcesPA forms and contact information available at bcbsil.com/provider or on the member ID card.
    ValidityPA approvals have defined validity periods; maintenance medication exceptions described in PA validity rules.
    QL (repeated)
    QL (repeated) — noteQL entries throughout the formulary set permitted dispensing quantities over specified timeframes; see the product row for exact QL amounts.
    Exception handlingProviders may request exceptions with supporting documentation if greater quantity is medically necessary.
    ConsequencesDispensing beyond QL without authorization may leave the member responsible for full cost of excess.
    SP (repeated)
    SP (repeated) — conciseSP denotes specialty pharmacy handling and appears frequently next to high-cost or complex therapies across the formulary.
    Associated controlsSP items often require PA, may be LD, and have QL specifications.
    ExamplesCoagulation factors, HEMLIBRA, pegfilgrastim biosimilars, and many oral oncology agents are SP-designated.
    LD (repeated)
    LD (repeated) — conciseLD is repeatedly used for products with restricted distribution (notably inhaled antibacterials and many oncology agents).
    Fulfillment cautionCoverage may require use of the specified limited distribution channel; failing to follow it can prevent fulfillment.
    Common pairingLD often appears with PA, QL and SP in formulary rows.

    Initial Therapy Restrictions

    Initial therapy restrictions for selected GLP-1s

    Selected GLP-1 and combination oral agents have prior authorization or quantity limits listed.

    TRULICITY initial coverage: TRULICITY (dulaglutide) is listed with Coverage Requirements and Limits = PA, QL (4 pens/28 days).QL 4 pens/28 days

    Prior authorization required when PA is indicated on the product line.

    Step Therapy Requirements

    Step therapy topicSummary / policy language
    Step therapy requirementSome drugs are subject to step therapy (noted as 'ST'); the member may need to try another proven, cost‑effective medication before coverage is available. Providers may request step therapy exceptions which will be reviewed per policy.
    Documentation / exceptionsExceptions to step therapy may be requested by the prescriber or member; approvals and exception handling follow the issuer's standard processes and timelines.
    Step therapy topicSummary / policy language
    Monthly drug list updatesThe drug list is updated monthly; updates may add step therapy or other utilization restrictions (e.g., PA, QL). Check the monthly change chart for specific drugs and changes.
    Advance notice for restrictive changesBCBSIL will provide at least 60 days' prior notification to affected covered individuals for drugs moving to a higher tier, drug coverage exclusions, or stricter utilization review requirements.
    Step therapy topicSummary / policy language
    Step therapy flags present in KEYThe formulary KEY includes 'ST' (Step Therapy) among coverage flags; presence of 'ST' next to a drug indicates step therapy may apply.
    Specific sequences absent in excerptThis excerpt shows the ST flag in the key but does not include detailed step sequences for most products; refer to product‑level lines in the full formulary for specifics.
    Program elementSummary / policy language
    Step Therapy program element (ST)Step Therapy (ST) is defined as a program element in the formulary KEY indicating some drugs require prior trial of alternatives before coverage; ST appears in the legend but explicit chains are not present in this excerpt.
    Application guidanceWhen 'ST' appears next to a medication on its product line in the full formulary, providers must follow the indicated step requirements or request an exception.
    Step therapy flagSummary / policy language
    ST flag in KEYThe KEY includes 'ST' to denote Step Therapy; in this excerpt the flag exists but product‑specific step requirements are not detailed.
    Follow product lines for detailsSpecific step therapy requirements are shown on individual drug lines elsewhere in the full formulary when applicable.
    Step therapy indicatorSummary / policy language
    ST indicator presentThe formulary key lists ST as a coverage indicator; this indicates that step therapy may apply to some products where ST appears on product rows.
    Excerpt limitationThis excerpt does not include the detailed step requirements; consult the complete formulary product entries for the specific sequences.
    DrugCoverage Requirements and Limits
    FETZIMA (levomilnacipran)Coverage Requirements and Limits = ST (Step Therapy) per formulary entry.
    TRINTELLIX (vortioxetine)Coverage Requirements and Limits = ST (Step Therapy) per formulary entry.
    StatementSource guidance
    Step Therapy applies where 'ST' is indicatedPer the formulary KEY, 'ST' denotes Step Therapy; where 'ST' appears on product lines in the full formulary, step therapy requirements apply.
    Check product‑level entries for specificsThe excerpt shows the ST flag in the key but not the full step chains; consult the full drug list product rows for detailed requirements.
    ReferenceInterpretation
    Step therapy referenced in KEYSome entries reference 'ST' in the KEY indicating step therapy may apply to certain formulary items; this excerpt lacks step sequences for those items.
    Program implicationWhere ST is indicated on the product line in the full formulary, the member may need to satisfy step therapy prior to coverage or request an exception.
    Flag presencePolicy note
    ST flag may indicate requirementThe KEY includes ST; where products on the full formulary are flagged 'ST', step therapy may apply — this excerpt does not provide the specific step rules.
    Provider actionProviders should review product‑level entries and submit exception requests when clinically appropriate if step therapy would delay needed therapy.
    Example productCoverage annotation
    Risperidone ODT (risperidone orally disintegrating tab 0.25 mg)Coverage Requirements and Limits = QL (60 tablets/30 days), ST — risperidone ODT is explicitly shown with 'ST' in its entry.
    Asenapine TD patch (asenapine transdermal) — example from segmentSome formulations in the antipsychotic segment (e.g., asenapine transdermal patch entries) include 'ST' where step therapy applies (ST flagged in KEY and product rows).
    PresenceLimitation
    ST indicator present in KEYThe KEY enumerates ST among coverage flags; this signals step therapy usage on the formulary.
    No explicit sequences in excerptThis excerpt does not provide explicit step therapy sequences; product‑level detail is in the complete formulary listings.
    FlagInterpretation
    'ST' flag in formulary KEYThe formulary KEY includes 'ST' indicating Step Therapy; specific requirements are shown on individual drug lines in the full formulary when applicable.
    Excerpt scopeThe provided excerpt lacks detailed step chains; follow the full formulary product entries for exact step therapy requirements and exception procedures.

    Quantity and Dispensing Limits

    Site of Care and Distribution

    Note
    Note
    Note
    Note

    Background and Scope

    This outpatient prescription drug formulary is organized by therapeutic class using the U.S. Pharmacopeia (USP) classification. It identifies covered products, formulary tiers, and programmatic controls such as Prior Authorization (PA), Step Therapy (ST), and Quantity/Dispensing Limits (QL/DL). The listing also uses regulatory and special designators (for example, IC = Illinois Code Compliance and CW = Cost Waived) that affect coverage and member cost‑sharing. Coverage is subject to the member's specific benefit plan and any utilization management requirements shown on individual product lines.